SAINT BELLA Inc (2508) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of SAINT BELLA Inc HK$6.87, price HK$2.80, upside +145.4%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SAINT BELLA Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
15‑month range HK$2.72 – HK$8.80 · fair‑value band HK$5.15 – HK$8.59 · the HK$2.80 price screens below the HK$6.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow SAINT BELLA in your weekly email
Every Wednesday you see whether SAINT BELLA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Saint Bella Group Limited engages in the operation of postpartum care centers, home care services, and food products business in China, Hong Kong, Singapore, the United States, and internationally. It offers postpartum care services under the Saint Bella and Baby Bella brands; and software development, as well as manufactures and sells apparel.
Show more
Saint Bella Group Limited engages in the operation of postpartum care centers, home care services, and food products business in China, Hong Kong, Singapore, the United States, and internationally. It offers postpartum care services under the Saint Bella and Baby Bella brands; and software development, as well as manufactures and sells apparel. The company was formerly known as SAINT BELLA Inc. and changed its name to Saint Bella Group Limited in February 2026. Saint Bella Group Limited was founded in 2023 and is headquartered in Hangzhou, China.
Stock analysis
SAINT BELLA Inc (2508) currently trades at HK$2.80, while our model-based Fair Value estimate is HK$6.87, implying the stock looks roughly 59.2% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$35.43 per share, and 12 of the 15 models we run sit above the HK$2.80 price.
Bear case: the Asset-Based group reads lowest at HK$1.24, and 3 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$5.15 (bear) to HK$8.59 (bull), the price of HK$2.80 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SAINT BELLA Inc reported revenue of 1.0B CNY in FY2025 versus 259M CNY in FY2021, a compound +41.8%/yr. Reported net income was 408M CNY in FY2025.
Key figures
Market cap HK$2.1B (≈ $264M) · P/E ratio 10.7 · P/S ratio 4.19 · EPS (TTM) HK$0.0100 · Net margin 39.0% · Return on assets (EBIT) −3.5% · Operating margin 10.3% · Revenue (TTM) 1.0B CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at 145%, 2508 screens cheaper than that median.
Fair Value models
Bear HK$5.15Fair Value HK$6.87Bull HK$8.59
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0075 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+31.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.4%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−12.4% (2021) → 8.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 250 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+145.4% · Top 25%
Profitability
Return on assets4.1% · Above median
Net margin (TTM)39.0% · Top 25%
Operating margin (TTM)10.3% · Above median
Growth and dividend
Revenue growth35.3% · Top 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is SAINT BELLA Inc (2508) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$6.87 versus a price of HK$2.80, about +145% upside (undervalued).
What is the fair value of 2508?
Our model-based fair value for SAINT BELLA Inc is HK$6.87 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$2.80.
What is the quality score of 2508?
SAINT BELLA Inc has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SAINT BELLA Inc (2508)?
Our model-based price target is the fair value of HK$6.87 (as of Sep 27, 2026) from 15 valuation models. Cautious scenario HK$5.15, optimistic scenario HK$8.59. It is a calculation from audited fundamentals, not an analyst target.
What is the SAINT BELLA Inc stock forecast for 2026?
Our models put fair value at HK$6.87, about +145% upside versus a price of HK$2.80 (undervalued). Cautious scenario HK$5.15, optimistic scenario HK$8.59. The calculation is refreshed regularly with new filings.
What is the revenue of SAINT BELLA Inc (2508)?
SAINT BELLA Inc reported trailing-twelve-month revenue of about 1.0B CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of SAINT BELLA Inc (2508)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SAINT BELLA Inc it is HK$6.87 per share (as of Sep 27, 2026), against a price of HK$2.80. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is SAINT BELLA Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2508 trades below its calculated fair value: price HK$2.80, fair value HK$6.87, a gap of about +145% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2508?
No. The price is what the market pays today (HK$2.80); the fair value is what the company's own numbers justify (HK$6.87). For SAINT BELLA Inc the two are HK$4.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is SAINT BELLA Inc worth?
The market values SAINT BELLA Inc at about HK$2.1B (market capitalisation, as of Sep 27, 2026). Per share that is HK$2.80; our models calculate a fair value of HK$6.87 per share.
What do the bullish and bearish scenarios say about 2508?
Our models span a range for SAINT BELLA Inc: cautious scenario HK$5.15, base HK$6.87, optimistic HK$8.59 per share (as of Sep 27, 2026, price HK$2.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2508?
SAINT BELLA Inc trades at a price-to-earnings ratio of 10.7 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$6.87 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 6.3 (reported for FY2025: 3.7). Other multiples: P/B 1.8, P/S 1.7, EV/EBITDA 15.0.
How far is 2508 from its 52-week high?
SAINT BELLA Inc trades at HK$2.80, about 59% below its 52-week high of HK$6.81 and 3% above the low of HK$2.72 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$6.87 is for.
Which stocks are comparable to SAINT BELLA Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SAINT BELLA Inc stock attractive at the current price?
The data as of Sep 27, 2026: price HK$2.80, calculated fair value HK$6.87 (+145%), Quality Score 61/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2508 calculated?
We run SAINT BELLA Inc through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$6.87, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. SAINT BELLA Inc currently trades 59 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SAINT BELLA Inc (2508)?
The closing price on Sep 30, 2026 was HK$2.80. Our model-based fair value is HK$6.87, about +145% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SAINT BELLA Inc right now?
The price is below even our cautious bear case (HK$5.15). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of SAINT BELLA Inc
How large is the market capitalisation of SAINT BELLA Inc (2508)?
The market capitalisation of SAINT BELLA Inc is HK$2.1B (≈ $264M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SAINT BELLA Inc (2508)?
The price-to-sales ratio of SAINT BELLA Inc is 4.19 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SAINT BELLA Inc (2508)?
Earnings per share at SAINT BELLA Inc are HK$0.0100 (price ÷ EPS = P/E 10.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SAINT BELLA Inc (2508)?
The net margin of SAINT BELLA Inc is 39.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of SAINT BELLA Inc (2508)?
On an EBIT basis the return on assets of SAINT BELLA Inc is −3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SAINT BELLA Inc (2508)?
The operating margin of SAINT BELLA Inc is 10.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SAINT BELLA Inc (2508)?
Revenue at SAINT BELLA Inc is growing +35.3% versus a year earlier (3y avg +30.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SAINT BELLA Inc (2508) generate?
The free cash flow of SAINT BELLA Inc is −2.3M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch SAINT BELLA Inc in the live analysis
One click puts SAINT BELLA Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
